Clicky

Celyad SA(CYAD)

Description: Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.


Keywords: Biotechnology Life Sciences Biology Stem Cell Cardiovascular Disease In Vitro Stem Cell Therapy Induced Stem Cells Adult Stem Cell Therapies For Cardiovascular Disease

Home Page: www.celyad.com

CYAD Technical Analysis

Axis Business Park
Mont-Saint-Guibert, 1435
Belgium
Phone: 32 1 039 41 00


Officers

Name Title
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME Co-Founder, CFO, Interim CEO & Director
Mr. David Georges VP of Fin. & Admin.
Sara Zelkovic Communications & Investor Relations Director
Mr. Philippe Nobels Chief HR Officer & VP of HR
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. Chief Medical Officer
Ms. An Phan Head of Legal
Mr. Hannes Iserentant Head of Intellectual Property
Dr. Frédéric Lehmann VP of Clinical Devel. & Medical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6921
Price-to-Sales TTM: 12738.134
IPO Date: 2015-06-19
Fiscal Year End: December
Full Time Employees: 95
Back to stocks